Drug intelligence / Profile preview

IDE705

Development stage
Discontinued
Lead developer
IDEAYA Biosciences
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

IDE705 is a novel small molecule inhibitor targeting the helicase activity of DNA polymerase theta (Pol θ), also known as POLQ. It is being developed as a potential first-in-class therapy for solid tumors with homologous recombination deficiency (HRD). The drug is primarily investigated in combination with niraparib (a PARP inhibitor) to exploit synthetic lethality in HRD-positive cancers. IDE705 is under joint development by IDEAYA Biosciences and GSK and has entered Phase 1/2 clinical trials for advanced solid tumors[3][6][7]. Its mechanism involves inhibiting Pol θ-mediated DNA repair pathways that are critical for the survival of HR-deficient tumor cells.

Brand names
GSK101GSK-101GSK 101
Other names
Pol theta helicase inhibitorDNA polymerase theta helicase inhibitorPOLQ inhibitor
02

Targets

POLQ (DNA polymerase theta)

Beyond the preview

Go deeper on IDE705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDE705.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call